Helene Biomed Group White Paper 2026

This white paper presents a comprehensive analysis of one of the world’s largest real-world clinical datasets in stem cell therapy, comprising over 15,000 cases accumulated over more than a decade. The dataset provides a regulatory-grade real-world evidence (RWE) platform that bridges clinical practice and the development and commercialisation of Advanced Therapy Medicinal Products (ATMPs). By integrating multi-centre clinical operations with rigorous manufacturing controls, the study demonstrates the scalability, safety, and reproducibility required for global therapeutic deployment. Key contributions of this work include: Large-scale clinical validation: Continuous accumulation of over 15,000 cases across multiple disease areas, enabling statistically robust insights into safety and clinical implementation. Manufacturing and quality standardisation: Demonstration of reproducibility through defined Critical Quality Attributes (CQA), Critical Process Parameters (CPP), potency assays, and release criteria, ensuring consistent therapeutic performance. Mechanistic framework: Identification of core therapeutic mechanisms of mesenchymal stem cells (MSCs), including paracrine signaling, immunomodulation, and tissue regeneration. Regulatory alignment: Evidence supporting ATMP licensing, including successful regulatory positioning in the United Kingdom and the United Arab Emirates. Scalable clinical model: A multi-centre, multi-indication framework enabling expansion across global healthcare systems and regulatory environments. Commercialisation strategy: A platform-based approach leveraging out-licensing, co-development partnerships, and geographic expansion across APAC, EU, and GCC regions. Unlike conventional clinical studies, which are often limited in scale and duration, this dataset represents a qualitative shift in regenerative medicine evidence generation, enabling real-world validation of both clinical and manufacturing consistency. This work establishes a foundational model for the transition from real-world clinical practice to globally deployable regenerative therapeutics, positioning Helene Biomed as a scalable ATMP platform company in the evolving biopharmaceutical landscape.